Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Essa Pharma (NASDAQ: EPIX) shares cratered 73% from $5.20 to $1.40 Friday after the company said it was terminating its Phase II trial (NCT05075577) assessing masofaniten combined with enzalutamide vs
The consistently high reviews for responsiveness suggest a team that actually answers questions, something not every telehealth provider delivers
Semaglutide compares well with sitagliptin AT THE ADA ANNUAL SCIENTIFIC SESSIONS NEW ORLEANS Semaglutide, a GLP-1 agonist for type 2 diabetes thats dosed weekly, was superior to daily sitagliptin in improving glycemic control and reducing body weight in people who are also on metformin and/or thiazolidinediones (TZDs), based on results from a phase III trial
Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry
Looking beyond Wegovy and Zepbound, there are several other drugs in development that provide even greater weight reduction and may have fewer side effects than the currently approved medicines
Apr 2017;18:23-30
US$ 21.41
US$ 25.36
US$ 28.78
US$ 29.79
US$ 21.47
US$ 24.22
